A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Phase 1/2
60
about 11 years
18+
4 sites in MA, MN, NY +1
Why this study is shown
What this study is about
Researchers are testing a new vaccine called EO2463 to treat indolent non-Hodgkin lymphoma. The trial will evaluate the safety, tolerability, and effectiveness of EO2463 alone or in combination with other medications like lenalidomide and rituximab.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive EO2463
- 2.Receive rituximab
- 3.Take lenalidomide
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear)), rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them)
oral (Oral Capsule), infusion
Primary: Phase 1: Recommended Phase 2 Dose | Adverse Events Assessment |, Phase 2: Complete Response Rate, Phase 2: Overall Response Rate
Secondary: Evaluation of Overall Survival
Oncology